Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...
An increasing demand for gene therapies is focusing the industry on enhancing production capabilities, transitioning from ...
Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...
News-Medical.Net on MSN
Researchers develop a versatile tool for controlling gene activity
Investigators at Weill Cornell Medicine have developed a versatile and non-toxic technology for controlling the activity of ...
For decades, synthetic biologists have been developing gene circuits that can be transferred into cells for applications such as reprogramming a stem cell into a neuron or generating a protein that ...
Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...
Scientists have successfully created immature human egg-like cells from skin-derived stem cells, a significant step in ...
In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...
A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...
A red quarter of a circle with the words 'The Quarter Mark' beside it. A year-long series looking back on the most significant moments of the past 25 years, how they changed our world, and how they ...
Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback